HOME >> BIOLOGY >> NEWS
Black women with early stage breast cancer less likely to receive full course of chemotherapy

Black women with stage I or II breast cancer are more likely than their counterparts of other races to abandon chemotherapy before completing their full course of treatment, according to a recent Columbia University Medical Center study.

Published in the Journal of Clinical Oncology (Sept. 20, 2005), the findings shed new light on why breast black cancer patients experience lower survival rates than other women, despite a lower incidence.

"This study is the first to correlate early termination of chemotherapy with racial disparities in breast cancer outcomes," said Dawn Hershman, M.D., M.S., assistant professor of medicine and epidemiology at Columbia University College of Physicians & Surgeons and the Mailman School of Public Health, and the study's lead investigator.

Dr. Hershman and her research team set out to study the association between race and survival with duration of treatment and number of completed chemotherapy cycles. They analyzed the data of 472 stage I and II breast cancer patients enrolled in the tumor registry of the Henry Ford Health System, a large Detroit-area healthcare provider, between 1996 and 2001.

The investigators determined that women who discontinued treatment were more likely to be black and more likely to die than those who completed full chemotherapy cycles. Key findings include:

  • Only 68 percent of black patients (136 out of 202 total) -- compared to 76 percent of white patients (206 out of 270 total) -- completed all prescribed cycles of chemotherapy.
  • 93 percent of all white patients in the study group were alive five years after diagnosis; compared to 81 percent of black patients.
  • A significant number of patients -- 130 out of 472 subjects, nearly 28 percent of the total study population -- did not receive complete treatment (defined here as less than 85 percent of the number of expected cycles).
  • The overall five-year survival rate for the total pat
    '"/>


Contact: Elizabeth Streich
eas2125@columbia.edu
212-305-6535
Columbia University Medical Center
12-Oct-2005


Page: 1 2

Related biology news :

1. Wiley to acquire Blackwell Publishing (Holdings) Ltd.
2. Elizabeth Blackburn and Janet Rowley awarded
3. Acute sleep deprivation leads to changes in nighttime urine production for men and women
4. Research aims to identify markers for menopausal women at risk for deadly blood clot
5. The female advantage in kidney disease does not extend to diabetic women
6. Progesterone therapy and preterm birth: More evidence helps identify women who can benefit
7. New model for autism suggests women carry the disorder and explains age as a risk factor
8. Awards celebrating women and biotech brilliance
9. High blood pressure medication strategy proves effective in Hispanic women
10. Study finds Western-style meat-sweet diet increases risk of breast cancer in postmenopausal women
11. New research shows vaginal bacteria vary among healthy women, need customized treatment

Post Your Comments:
(Date:3/12/2015)... 12, 2015 Beta Systems ... and access management (IAM) solution for a fixed ... Beta System,s new IAM package, customers benefit from ... from multiple IAM implementations across different industries. The ... well as any necessary services and consulting. It ...
(Date:3/11/2015)... Mar. 11, 2015 Research and Markets ... "Access Control Market by Product, Application & By ... report to their offering. , This report ... reach $10.4 billion by 2020, with an estimated CAGR ... covers the products types such as contact cards & ...
(Date:3/10/2015)... NEW YORK , March 10, 2015  Continuing ... and the Unexpected, Hammacher Schlemmer introduces The Eye ... user,s identity before granting access to secure websites or ... trusted to verify travelers at international borders, the device ... 240 distinctive pattern points of the iris, converting them ...
Breaking Biology News(10 mins):Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
(Date:3/26/2015)... ReliantHeart, Inc., an innovative supplier of advanced mechanical ... transit-time flow measurement solutions, are collaborating on a miniature ... the HeartAssist5® Left Ventricular Assist Device (LVAD). ... and peace of mind. , The Transonic flow ... 1/6th of the power required by earlier flow board ...
(Date:3/25/2015)... 26, 2015 Agnition announced today that ... American Farmer, airing for the first time at 7:30 ... American Farmer will explore the extremely important role soil ... with a patented Microbial Catalyst™ technology that enhances soil ... The segment will air again on April 28. , ...
(Date:3/25/2015)... (PRWEB) March 25, 2015 Laboratory ... Top-Loading Balances and Analytical Balances to get best-performing ... line of weighing balances from the trusted brand ... Balances increase your efficiency by providing a ... of samples. Weighing modes include parts counting, percent ...
(Date:3/25/2015)... Francisco, CA (PRWEB) March 25, 2015 ... Support for Novel Mechanism of Action in Neuromuscular ... 25, 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... fast skeletal muscle troponin activator tirasemtiv in the ... a Phase IIa “Evidence of Effect” or hypothesis-generating ...
Breaking Biology Technology:LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2New Economical Top-Loading and Analytical Symmetry Balances from Cole-Parmer 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6
Cached News: